Meet our startups
Neuroscience • Diagnostics • Digital
Semi-finalist WaveCap - Oxford, United Kingdom - Non-invasive neurostimulation for early onset seizure detection & treatment using novel machine learning algorithm on EEG

Over 50 million people worldwide suffer from epilepsy (WHO). The result of sudden, brief, excessive electrical discharges of neurons, epilepsy is characterized by seizures that lead to unconsciousness, sensory disturbance, and disruption in mood and mental function. In addition to physical trauma, epilepsy carries the devastating consequence of social stigma associated with it. Across the world these social consequences cause even more suffering at times than the seizures themselves, as they affect all facets of life, such as education, employment, and personal relationships. Thus, devising an effective and sustainable treatment for epilepsy and reducing the suffering of millions is both an urgent challenge and a unique and worthwhile opportunity.


Our technology provides a combination of EEG with transcranial direct current stimulation (tDCS) for pre-seizure treatment of episodes in epileptic patients. With our technology, proprietary machine learning (ML) algorithms first detect pre-seizure activity through EEG recording streams. Then tDCS is used to target and stimulate the specific area of the brain predicted by our algorithm to have a seizure with high accuracy and specificity in a time span of milliseconds.



  • OneStart Europe 2015 Semi-finalist


  • Provisional patent for the US and EU filed
  • Technology developed outside of any academic institutes

David Wei Jia, Co-founder, University of Oxford

Ignacio Perez Pozuelo, Co-founder, University of Oxford

Scientific Advisory Board

  • Felipe Fregni, MD, PhD, Director of the Laboratory of Neuromodulation, Spaulding Rehabilitation Hospital, Harvard Medial School and Associate Professor of Neurology, Physical Medicine and Rehabilitation, Harvard Medical School.
  • Mkael Symmonds, MD, PhD, Assistant Professor at Nuffield Department for Clinical Neurosciences, University of Oxford Center for Epilepsy Research
Deborah Harland
Partner, SR One + more
I joined SR One in 2005 to establish the firm's European investment office. I have extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during more than 20 year tenure in the pharmaceutical industry. I am currently a member of the Board of Directors of Mission Therapeutics, Bicycle Therapeutics, Atopix Therapeutics, AtoxBio, f-star and VH Squared.
Mark Phillips
Executive advisor to biotech and healthtech companies + more
I am a senior executive with over 30 years experience in the pharmaceutical, diagnostics and life sciences industries. I have led global teams in research and development, and in manufacturing to create new businesses and transform performance. I am passionate about building new capabilities in teams and individuals (through coaching), and working with smaller businesses and academia to translate ideas and strategy into products and results.

Please enter your details to send the team a pitch deck request:

Captcha image